Stock Taper
OmniAb, Inc. provides innovative antibody discovery platforms using genetically engineered transgenic animals to enable the development of next-generation therapeutics and bispecific antibodies.

OmniUltra, OmniAb's advanced platform using engineered chickens, enables novel antibody and peptide discovery to develop next-generation therapeutics like bispecifics, CAR-T, and radioligands targeting challenging biological sites.
| Icon | PRODUCT | Q1-2025 | Q2-2025 | Q4-2025 | Q2-2026 |
|---|---|---|---|---|---|
![]() | Service | $1.95M | $1.94M ▼ | $3.38M ▲ | $2.47M ▼ |
![]() | Royalty | $188K | $111K ▼ | $579K ▲ | $266K ▼ |
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
VOR | $24.85 | COMPARE |
OBIO | $4.92 | COMPARE |
CGEN | $2.58 | COMPARE |
IVVD | $0.81 | COMPARE |
TARA | $3.94 | COMPARE |
CHRS | $1.42 | COMPARE |
MDWD | $13.29 | COMPARE |
NTHI | $5.15 | COMPARE |